<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01327625</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-ALLO-041</org_study_id>
    <nct_id>NCT01327625</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Azithromycin-based Therapy for Bronchiolitis Obliterans</brief_title>
  <official_title>A Pilot Study Evaluating the Efficacy of Azithromycin, N-acetylcystein and Inhaled Corticosteroid Combination Therapy for Bronchiolitis Obliterans After Allogeneic Hematopoietic Cell Transpantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      [Study Objectives]

        -  To evaluate the efficacy of azithromycin, N-acetylcystein, and inhaled corticosteroid
           combination therapy in patients with bronchiolitis obliterans as a complication of
           allogeneic hematopoietic cell transplantation in terms of response rate at 6 months
           after treatment initiation based on the improvement of FEV1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Bronchiolitis obliterans (BO) is a graft-versus-host disease of respiratory organs.

        -  Prognosis of BO is very poor, and the overall outcome of patients who are involved in BO
           is very dismal.

        -  The mechanism of BO has been known to be associated with immune / non-immune response.

        -  Corticosteroid and immunosuppressants are recommended as a best current treatment
           options for BO, which have been not satisfactory.

        -  Many treatment options have been tried to improve the outcome of BO.

        -  Azithromycin, as an immune modulating agent, has been tried for the treatment of BO, and
           has been reported to show hopeful results.

        -  N-acetylcystein, as an antioxidative agent, has been tried for BO.

        -  Inhaled corticosteroid may help to improve airway inflammation and decrease the amount
           of systemic corticosteroid.

        -  These 3 drugs are widely used for other respiratory disease, have been proven to be
           safe, and have shown some efficacy for BO in various depth of evidence.

        -  In these rationale, we'd like to try the 3-drug combination for BO, to assess the
           efficacy and safety of these drug combination.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Preliminary reports of this study was too bad.
  </why_stopped>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate based on the improvement of FEV1</measure>
    <time_frame>6 months</time_frame>
    <description>Response rate at 6 months after treatment initiation based on the improvement of FEV1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate based on the degree of change in FEV1</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical benefit rate at 6 months after treatment initiation based on the degree of change in FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in FEV1 compared with pretreatment level</measure>
    <time_frame>6 months after treatment initiation</time_frame>
    <description>Change in FEV1 at 6 months after treatment initiation compared with pretreatment level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction rate in immunosuppressive agent / systemic corticosteroid</measure>
    <time_frame>6 months after treatment initiation</time_frame>
    <description>Reduction rate in immunosuppressive agent / systemic corticosteroid at 6 months after treatment initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation rate in immunosuppressive agent / systemic corticosteroid</measure>
    <time_frame>6 months after treatment initiation</time_frame>
    <description>Discontinuation rate in immunosuppressive agent / systemic corticosteroid at 6 months after treatment initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dose-intensity of immunosuppressive agent / systemic corticosteroid compared with pretreatment dose-intensity</measure>
    <time_frame>6 months after treatment initiation</time_frame>
    <description>Change in dose-intensity of immunosuppressive agent / systemic corticosteroid at 6 month after treatment initiation compared with pretreatment dose-intensity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event-free survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>1year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Graft vs Host Disease</condition>
  <condition>Bronchiolitis Obliterans</condition>
  <arm_group>
    <arm_group_label>Azithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient who are diagnosed as bronchiolitis obliterans according to the WHO criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azithromycin + N-acetylcystein + inhaled corticosteroid</intervention_name>
    <description>Azithromycin 500mg qd x 1 week --&gt; 250mg qod x 6 months
N-acetylcystein 200mg tid x 6 months
Fluticasone 250mcg puff x2/day x 6 months</description>
    <arm_group_label>Azithromycin</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who previously received allogeneic hematopoietic cell transplantation due to
             hematologic malignancy, bone marrow failure syndrome, and other compatible disease.

          -  Patients who are diagnosed as bronchiolitis obliterans (BO) according to the NIH
             diagnostic guideline which is suggested as below.

          -  Patients should be 15 years of age or older, but younger than 75 years.

          -  Patients should have estimated life expectancy of more than 3 months.

          -  Patients must have adequate hepatic function (bilirubin less than 3.0 ㎎/㎗, AST and ALT
             less than three times the upper normal limit).

          -  Patients must have adequate renal function (creatinine less than 2.0 ㎎/㎗).

        Exclusion Criteria:

          -  Presence of significant active infection

          -  Presence of uncontrolled bleeding

          -  Any coexisting major illness or organ failure

          -  Patients with a psychiatric disorder or mental deficiency severe as to make compliance
             with the treatment unlike, and making informed consent impossible.

          -  Nursing women, pregnant women, women of childbearing potential who do not want
             adequate contraception

          -  Patients with a diagnosis of prior malignancy unless disease-free for at least 5 years
             following therapy with curative intent (except curatively treated nonmelanoma skin
             cancer, in situ carcinoma, or cervical intraepithelial neoplasia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dae-Young Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Patriarca F, Poletti V, Costabel U, Battista ML, Sperotto A, Medeot M, Toffoletti E, Fanin R. Clinical presentation, outcome and risk factors of late-onset non-infectious pulmonary complications after allogeneic stem cell transplantation. Curr Stem Cell Res Ther. 2009 May;4(2):161-7. Review.</citation>
    <PMID>19442201</PMID>
  </reference>
  <reference>
    <citation>Afessa B, Peters SG. Major complications following hematopoietic stem cell transplantation. Semin Respir Crit Care Med. 2006 Jun;27(3):297-309. Review.</citation>
    <PMID>16791762</PMID>
  </reference>
  <reference>
    <citation>Nishio N, Yagasaki H, Takahashi Y, Muramatsu H, Hama A, Tanaka M, Yoshida N, Watanabe N, Kudo K, Yoshimi A, Kojima S. Late-onset non-infectious pulmonary complications following allogeneic hematopoietic stem cell transplantation in children. Bone Marrow Transplant. 2009 Sep;44(5):303-8. doi: 10.1038/bmt.2009.33. Epub 2009 Apr 6.</citation>
    <PMID>19349954</PMID>
  </reference>
  <reference>
    <citation>Williams KM, Chien JW, Gladwin MT, Pavletic SZ. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA. 2009 Jul 15;302(3):306-14. doi: 10.1001/jama.2009.1018.</citation>
    <PMID>19602690</PMID>
  </reference>
  <reference>
    <citation>Sato M, Keshavjee S. Bronchiolitis obliterans syndrome: alloimmune-dependent and -independent injury with aberrant tissue remodeling. Semin Thorac Cardiovasc Surg. 2008 Summer;20(2):173-82. doi: 10.1053/j.semtcvs.2008.05.002. Review.</citation>
    <PMID>18707652</PMID>
  </reference>
  <reference>
    <citation>Duncan CN, Buonanno MR, Barry EV, Myers K, Peritz D, Lehmann L. Bronchiolitis obliterans following pediatric allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008 Jun;41(11):971-5. doi: 10.1038/bmt.2008.19. Epub 2008 Feb 25.</citation>
    <PMID>18297116</PMID>
  </reference>
  <reference>
    <citation>Ditschkowski M, Elmaagacli AH, Trenschel R, Peceny R, Koldehoff M, Schulte C, Beelen DW. T-cell depletion prevents from bronchiolitis obliterans and bronchiolitis obliterans with organizing pneumonia after allogeneic hematopoietic stem cell transplantation with related donors. Haematologica. 2007 Apr;92(4):558-61.</citation>
    <PMID>17488669</PMID>
  </reference>
  <reference>
    <citation>Huisman C, van der Straaten HM, Canninga-van Dijk MR, Fijnheer R, Verdonck LF. Pulmonary complications after T-cell-depleted allogeneic stem cell transplantation: low incidence and strong association with acute graft-versus-host disease. Bone Marrow Transplant. 2006 Oct;38(8):561-6. Epub 2006 Sep 4.</citation>
    <PMID>16953211</PMID>
  </reference>
  <reference>
    <citation>Yoshihara S, Tateishi U, Ando T, Kunitoh H, Suyama H, Onishi Y, Tanosaki R, Mineishi S. Lower incidence of Bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning. Bone Marrow Transplant. 2005 Jun;35(12):1195-200.</citation>
    <PMID>15852024</PMID>
  </reference>
  <reference>
    <citation>Santo Tomas LH, Loberiza FR Jr, Klein JP, Layde PM, Lipchik RJ, Rizzo JD, Bredeson CN, Horowitz MM. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest. 2005 Jul;128(1):153-61. Erratum in: Chest. 2006 Jan;129(1):216.</citation>
    <PMID>16002929</PMID>
  </reference>
  <reference>
    <citation>Xu J, Torres E, Mora AL, Shim H, Ramirez A, Neujahr D, Brigham KL, Rojas M. Attenuation of obliterative bronchiolitis by a CXCR4 antagonist in the murine heterotopic tracheal transplant model. J Heart Lung Transplant. 2008 Dec;27(12):1302-10. doi: 10.1016/j.healun.2008.08.010.</citation>
    <PMID>19059110</PMID>
  </reference>
  <reference>
    <citation>Hildebrandt GC, Granell M, Urbano-Ispizua A, Wolff D, Hertenstein B, Greinix HT, Brenmoehl J, Schulz C, Dickinson AM, Hahn J, Rogler G, Andreesen R, Holler E. Recipient NOD2/CARD15 variants: a novel independent risk factor for the development of bronchiolitis obliterans after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008 Jan;14(1):67-74.</citation>
    <PMID>18158963</PMID>
  </reference>
  <reference>
    <citation>Medoff BD, Wain JC, Seung E, Jackobek R, Means TK, Ginns LC, Farber JM, Luster AD. CXCR3 and its ligands in a murine model of obliterative bronchiolitis: regulation and function. J Immunol. 2006 Jun 1;176(11):7087-95.</citation>
    <PMID>16709871</PMID>
  </reference>
  <reference>
    <citation>Jaramillo A, Smith CR, Maruyama T, Zhang L, Patterson GA, Mohanakumar T. Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol. 2003 May;64(5):521-9.</citation>
    <PMID>12691702</PMID>
  </reference>
  <reference>
    <citation>Belperio JA, DiGiovine B, Keane MP, Burdick MD, Ying Xue Y, Ross DJ, Lynch JP 3rd, Kunkel SL, Strieter RM. Interleukin-1 receptor antagonist as a biomarker for bronchiolitis obliterans syndrome in lung transplant recipients. Transplantation. 2002 Feb 27;73(4):591-9.</citation>
    <PMID>11889437</PMID>
  </reference>
  <reference>
    <citation>Belperio JA, Keane MP, Burdick MD, Lynch JP 3rd, Xue YY, Berlin A, Ross DJ, Kunkel SL, Charo IF, Strieter RM. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest. 2001 Aug;108(4):547-56.</citation>
    <PMID>11518728</PMID>
  </reference>
  <reference>
    <citation>Vilchez RA, Dauber J, Kusne S. Infectious etiology of bronchiolitis obliterans: the respiratory viruses connection - myth or reality? Am J Transplant. 2003 Mar;3(3):245-9. Review.</citation>
    <PMID>12614277</PMID>
  </reference>
  <reference>
    <citation>Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant. 2003 Oct;9(10):657-66.</citation>
    <PMID>14569562</PMID>
  </reference>
  <reference>
    <citation>Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S106-14. doi: 10.1016/j.bbmt.2009.11.002. Epub 2009 Nov 5. Review.</citation>
    <PMID>19896545</PMID>
  </reference>
  <reference>
    <citation>Maimon N, Lipton JH, Chan CK, Marras TK. Macrolides in the treatment of bronchiolitis obliterans in allograft recipients. Bone Marrow Transplant. 2009 Jul;44(2):69-73. doi: 10.1038/bmt.2009.106. Epub 2009 May 11. Review.</citation>
    <PMID>19430505</PMID>
  </reference>
  <reference>
    <citation>Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2008 Jan 15;85(1):36-41. doi: 10.1097/01.tp.0000295981.84633.bc.</citation>
    <PMID>18192909</PMID>
  </reference>
  <reference>
    <citation>Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2004 May 15;77(9):1465-7.</citation>
    <PMID>15167610</PMID>
  </reference>
  <reference>
    <citation>Khalid M, Al Saghir A, Saleemi S, Al Dammas S, Zeitouni M, Al Mobeireek A, Chaudhry N, Sahovic E. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J. 2005 Mar;25(3):490-3.</citation>
    <PMID>15738293</PMID>
  </reference>
  <reference>
    <citation>Meloni F, Cascina A, Miserere S, Perotti C, Vitulo P, Fietta AM. Peripheral CD4(+)CD25(+) TREG cell counts and the response to extracorporeal photopheresis in lung transplant recipients. Transplant Proc. 2007 Jan-Feb;39(1):213-7.</citation>
    <PMID>17275508</PMID>
  </reference>
  <reference>
    <citation>Duncan CN, Barry EV, Lehmann LE. Tolerability of pravastatin in pediatric hematopoietic stem cell transplant patients with bronchiolitis obliterans. J Pediatr Hematol Oncol. 2010 Apr;32(3):185-8. doi: 10.1097/MPH.0b013e3181d32184.</citation>
    <PMID>20186101</PMID>
  </reference>
  <reference>
    <citation>Wuyts WA, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE, Demedts MG, Verleden GM. N-acetylcysteine inhibits interleukin-17-induced interleukin-8 production from human airway smooth muscle cells: a possible role for anti-oxidative treatment in chronic lung rejection? J Heart Lung Transplant. 2004 Jan;23(1):122-7.</citation>
    <PMID>14734137</PMID>
  </reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2011</study_first_submitted>
  <study_first_submitted_qc>March 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2011</study_first_posted>
  <last_update_submitted>July 8, 2014</last_update_submitted>
  <last_update_submitted_qc>July 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Dae-Young Kim</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Allogeneic hematopoietic cell transplantation</keyword>
  <keyword>Graft versus host disease</keyword>
  <keyword>Bronchiolitis obliterans</keyword>
  <keyword>Azithromycin</keyword>
  <keyword>N-acetylcystein</keyword>
  <keyword>Fluticasone</keyword>
  <keyword>Inhaled steroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

